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Although neural-immune cross-talk during disease and/or trauma has been studied for many 
years, the dogma has been that there is little interaction between the immune and nervous 
systems in healthy individuals. This belief was historically based on indications that the 
blood-brain barrier (BBB) blocks immune cell infiltration into the central nervous system 
(CNS), leading to limited immune responses in the CNS, and by a lack of classical immune 
proteins in the brain (Murphy and Sturm 1923; Joly et al. 1991). However, recent 
observations from both clinical and basic science research have caused a paradigm shift in 
our understanding of neural-immune interactions, indicating clearly that there is extensive 
communication between these systems (McAllister and van de Water 2009). There is now 
clear evidence that environmental insults that alter the immune response can affect brain 
development as well as behavior (Meyer et al. 2011; Patterson 2009). Moreover, mouse 
models of neurodevelopmental disorders have provided strong support for immune 
involvement in CNS development and disease (Patterson 2009; Patterson 2011). Finally, 
several different kinds of immune molecules, including cytokines, major histocompatibility 
complex (MHC) proteins, and complement, are expressed in the developing and adult brain 
and have critical functions in brain development and plasticity (Stephan et al. 2012; Garay 
and McAllister 2009; Shatz 2009; Elmer and McAllister 2012). In this Special Issue, we 
include reviews covering a range of topics from epidemiology, indicating a role for immune 
dysregulation in neurodevelopmental disorders, to basic mechanisms underlying the effects 
of immune molecules in brain development and disease.
Interest in neural-immune crosstalk has gained momentum as evidence accumulates 
regarding the potential involvement of immune dysregulation in many neurological and 
psychiatric disorders, as well as in healthy brain function. In addition to its well-documented 
role in trauma, neural inflammation is clearly present in several degenerative diseases, 
including Alzheimer’s and Parkinson’s disease (Lucin and Wyss-Coray, 2009). CNS 
resident immune cells, called microglia, may lose activity with age, leading to inefficient 
clearance of toxic protein aggregates that characterize neurodegenerative diseases. 
Moreover, the BBB becomes more permeable with healthy aging, which is accompanied by 
increased immune activation, expression of stress-induced and inflammatory genes, and 
CNS immune cell infiltration (Lucin and Wyss-Coray, 2009). Finally, neural-immune 
crosstalk may even occur in the non-diseased brain since BBB permeability is altered by 
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many factors, including addictive drugs, toxins, subclinical infection, stress, and some 
medications (van den Pol, 2009).
In addition to a clear role for neural-immune crosstalk in degenerative disorders, there is 
rapidly increasing evidence for immune involvement in neurodevelopmental disorders. 
Although several neurodevelopmental disorders are caused by mutations in single genes, 
two of the most common disorders of neural development—autism spectrum disorders 
(ASD) and schizophrenia (SZ)—appear to be caused by a combination of mutations and 
environmental exposures. Interestingly, many of the diverse range of environmental factors 
that confer elevated risk for these disorders converge on an altered immune response. Each 
of the reviews included in this Special Issue discuss this issue from distinct perspectives. 
Alan Brown describes the increasingly compelling epidemiological evidence that several 
types of maternal infection increase the risk for offspring to develop ASD or SZ. This 
review also summarizes recent studies that report correlations between maternal cytokines, 
which are immune signaling molecules, and risk for these disorders. In addition to maternal 
infection, there is also ample evidence for changes in expression of immune genes in ASD 
and SZ patients. Michel and Mirnics summarize evidence that immune genes contribute to 
increased risk for ASD and SZ and expression of these genes is altered in postmortem ASD 
and SZ brains. Needleman and McAllister focus specifically on the evidence for a role for 
the diverse array of genes within the major histocompatibility complex (MHC) in conferring 
increased risk for ASD. Finally, in addition to ASD and SZ, immune dysregulation is also 
centrally involved in fetal alcohol spectrum disorder (FASD); Kane, Phelan, and Drew 
comprehensively describe this disorder and the role of immune cells in mediating it. 
Together, data from several of the approaches covered in these reviews converges on the 
conclusion that environmental and genetic changes in immune responses contribute 
significantly to ASD, SZ, and FASD.
Neuroimmunology research has also recently made dramatic advances in understanding how 
maternal infection and prenatal exposures contribute to neurodevelopmental disorders. An 
understudied, but clearly critical, component of this pathway is the placenta. Hsiao and 
Patterson describe how the placenta regulates maternal-fetal interactions, focusing on 
placental regulation of the effects of maternal immune activation (MIA) on the developing 
fetus. This review also discusses the intriguing evidence for a role for the placenta in 
prenatal programming of neurodevelopmental disorders. The placenta is generally thought to 
limit the maternal immune response from negatively impacting fetal development. While 
maternal antibodies are passed across the placenta to the fetus to confer passive immunity, 
some mothers generate antibodies that cross into the fetus and target fetal tissues. Because 
the BBB is not fully developed during this period of gestation, these maternal antibodies can 
enter the brain. It is well-known that autoantibodies from mothers with autoimmune 
disorders cross the BBB and may contribute to cognitive impairments in offspring (Bhat and 
Steinman, 2009). van de Water, Fox, and Amaral describe recent findings showing that 
specific maternal antibodies that cross the BBB in offspring and recognize fetal brain 
proteins are associated with increased risk for ASD.
The neural-immune theory of many neurodevelopmental disorders is also supported by 
extensive evidence from animal models. Mouse models of the MIA risk factor demonstrate 
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that maternal infection leads to abnormal behaviors in offspring that are consistent with SZ 
and include the three core symptoms of ASD. These models are being studied in many 
laboratories and their ability to model the anatomical, pharmacological, and behavioral 
changes in ASD and SZ are discussed in several reviews in this Special Issue. Michel and 
Mirnics introduce the mouse MIA model and this model is further discussed in the context 
of genes within the MHC by Needleman and McAllister. The role of the placenta in 
regulating and facilitating the effects of MIA in the offspring is discussed by Hsiao and 
Patterson. Harvey and Boksa compare and contrast the many pre- and postnatal MIA mouse 
models. This review critically assesses the strengths and potential pitfalls of these models 
and their relevance to neurodevelopmental disorders in general, and to ASD and SZ in 
particular. Mouse models of FASD have also revealed underlying pathology and the role of 
microglia in this disorder as reviewed by Kane, Phelan, and Drew. Finally, van de Water, 
Fox, and Amaral discuss recent reports in both mouse and non-human primate models that 
have revealed detrimental effects of maternal antibodies on brain development and lead to 
ASD-like behaviors.
Although the epidemiological evidence suggesting that immune dysregulation predisposes 
offspring to ASD and SZ is increasingly compelling, little is known about how immune 
dysregulation during early development causes behaviors and neuropathology characteristic 
of ASD, SZ, or FASD in offspring. The role of microglia in contributing to FASD is 
reviewed by Kane, Phelan, and Drew. Several microglial proteins within the MHC may also 
contribute to ASD, as summarized by Needleman and McAllister. Most of the evidence to 
date, however, strongly suggests that immune signaling molecules called cytokines are 
essential for a peripheral immune response to alter brain development. The central role for 
both maternal and fetal cytokines in mediating the effects of MIA on brain development are 
described by Michel and Mirnics, Needleman and McAllister, Hsiao and Patterson, and 
Harvey and Boksa. Although the effects of many cytokines remain to be investigated, one in 
particular, the chemokine CXCL12 (also known as SDF-1) has been extensively studied for 
its role in brain development. Zhu and Murakami summarize that the influence that 
CXCL12 has on many stages of neural development and illustrate the point that the timing 
of changes in cytokine levels caused by genetic or environmental factors will strongly 
influence the types of developmental processes affected.
Despite the rapid recent progress in the field of neuroimmunology in the past few years, 
many questions remain to be addressed. First, how central is immune dysregulation to 
neurodevelopmental disorders such as ASD, SZ, and FASD? Does immune dysregulation 
generally predispose individuals to neurodevelopmental disorders or is it the primary cause 
of subsets of these disorders (an important question debated by Harvey and Boksa)? What 
role does the placenta play in this process and can transfer of detrimental maternal cytokines 
or antibodies to the fetus be prevented at the level of the placenta? What is the molecular 
pathway triggered by maternal cytokines resulting from MIA that leads to the 
neuropathology and altered behaviors characteristic of ASD and SZ? Finally, which 
cytokines are the most important in causing neurodevelopmental disorders and can they, or 
their receptors and/or signaling cascades, be targeted to prevent the MIA phenotype? 
Answering these questions is essential to determine if immune molecules present novel 
therapeutic approaches in the near future for these complex neurodevelopmental disorders.
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